Is NCT06126276 recruiting in Los Angeles, CA?

Yes, NCT06126276 is currently recruiting participants at its Los Angeles, CA location. This her2+ solid tumors clinical trial is actively enrolling qualified participants.

How do I join the her2+ solid tumors clinical trial in Los Angeles?

To join this clinical trial in Los Angeles, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Los Angeles clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

HER2+ Solid Tumors Clinical Trial in Los Angeles, CA

About This HER2+ Solid Tumors Study in Los Angeles

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-expres

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N5 based on the presence of an actionable mutation as defined in EAY191

Patients must have a HER2 amplified solid tumor except breast cancer.

If IHC is 0 or 1+, patient (pt) is NOT ELIGIBLE regardless of in situ hybridization (ISH)/FISH or next generation sequencing (NGS) status

If IHC is 3+, pt IS ELIGIBLE regardless of ISH/FISH or NGS status

If IHC is 2+, ISH/FISH OR NGS must be positive for the patient to be ELIGIBLE. Otherwise, pt is NOT ELIGIBLE

If IHC is unknown and…

ISH/FISH is positive, independent of NGS results, the patient IS ELIGIBLE

ISH/FISH is negative and NGS positive with ≥ 7 copies, the patient IS ELIGIBLE

Patients must have recurrent or persistent disease

No known evidence of RB1 loss or deletion including copy number loss or deleterious mutation

Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191)

Patients must have measurable disease based on RECIST 1.1. A second measurable lesion outside of the biopsiable lesion is required

Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression for 3 months or more and patient is not on steroids and is asymptomatic

No known leptomeningeal disease

Patients may have received up to 5 prior lines of systemic therapy

Prior therapy with trastuzumab or pertuzumab, either alone or in combination, antibody drug conjugates (ADC) such as DS8201a or T-DM1 is allowed

No prior therapy with HER2 targeting tyrosine kinase inhibitors (TKI) such as neratinib or tucatinib

No prior therapy with CDK4/6 inhibition

No cancer directed therapy within 3 weeks prior to registration. For oral therapy, the washout can be reduced to greater than or equal to 5 half lives of the drug. No HER2 targeting ADCs within 30 days prior to registration

Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2

Not pregnant and not nursing

Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3

Platelets ≥ 100,000 cells/mm\^3

Hemoglobin ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin (Hgb) ≥ 9 g/dl is acceptable)

Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula

Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (ULN)

Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

No active infection requiring parenteral antibiotics

No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube

No current evidence of malabsorption or chronic diarrhea or any other significant gastro-intestinal disease (e.g gastrectomy, ileal bypass, Crohn's disease, gastroparesis), associated with moderate to severe diarrhea (grade 2 or more) or inability to tolerate oral therapy

No lung disease causing dyspnea at rest

No interstitial lung disease with ongoing signs and symptoms at the time of registration

No history of allergic reaction to the study agents, compound of similar chemical or biologic composition of the study agents or any of their excipients

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06126276) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HER2+ Solid Tumors Treatment Options in Los Angeles, CA

If you're searching for her2+ solid tumors treatment options in Los Angeles, CA, this clinical trial (NCT06126276) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced her2+ solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all her2+ solid tumors clinical trials near you to find additional studies recruiting in your area.

HER2+ Solid Tumors Clinical Trial in Los Angeles, CA

Expert Care in Los Angeles

IRB Approved

No-Cost Care

Apply for This Los Angeles Location

Why Participate?

Simple Process